WuXi AppTec Co., Ltd.

SHSE:603259 Stock Report

Market Cap: CN¥140.7b

WuXi AppTec Valuation

Is 603259 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603259 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603259 (CN¥49.63) is trading below our estimate of fair value (CN¥106.92)

Significantly Below Fair Value: 603259 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603259?

Key metric: As 603259 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603259. This is calculated by dividing 603259's market cap by their current earnings.
What is 603259's PE Ratio?
PE Ratio17.8x
EarningsCN¥8.06b
Market CapCN¥140.70b

Price to Earnings Ratio vs Peers

How does 603259's PE Ratio compare to its peers?

The above table shows the PE ratio for 603259 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.1x
300759 Pharmaron Beijing
25.2x7.0%CN¥43.2b
300347 Hangzhou Tigermed Consulting
55.1x36.1%CN¥49.0b
688131 Shanghai Haoyuan Chemexpress
50.9x37.9%CN¥7.8b
688710 Shanghai Innostar Biotechnology
37.2xn/aCN¥5.5b
603259 WuXi AppTec
17.8x15.4%CN¥140.7b

Price-To-Earnings vs Peers: 603259 is good value based on its Price-To-Earnings Ratio (17.8x) compared to the peer average (42.1x).

Price to Earnings Ratio vs Industry

How does 603259's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
603259 17.8xIndustry Avg. 31.9xNo. of Companies8PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603259 is good value based on its Price-To-Earnings Ratio (17.8x) compared to the Asian Life Sciences industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 603259's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603259 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.8x
Fair PE Ratio33.2x

Price-To-Earnings vs Fair Ratio: 603259 is good value based on its Price-To-Earnings Ratio (17.8x) compared to the estimated Fair Price-To-Earnings Ratio (33.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603259 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥49.63
CN¥63.21
+27.4%
27.3%CN¥96.12CN¥20.50n/a18
Nov ’25CN¥51.15
CN¥63.21
+23.6%
27.3%CN¥96.12CN¥20.50n/a18
Oct ’25CN¥52.36
CN¥58.57
+11.9%
30.5%CN¥97.00CN¥20.50n/a17
Sep ’25CN¥39.18
CN¥58.36
+49.0%
29.9%CN¥97.00CN¥20.50n/a18
Aug ’25CN¥42.30
CN¥59.27
+40.1%
30.3%CN¥97.00CN¥20.50n/a18
Jul ’25CN¥38.66
CN¥68.33
+76.8%
32.0%CN¥128.00CN¥36.50n/a18
Jun ’25CN¥42.11
CN¥68.33
+62.3%
32.0%CN¥128.00CN¥36.50n/a18
May ’25CN¥43.67
CN¥70.31
+61.0%
29.8%CN¥128.00CN¥36.50n/a18
Apr ’25CN¥47.84
CN¥74.61
+56.0%
36.5%CN¥151.00CN¥36.50n/a18
Mar ’25CN¥55.02
CN¥117.68
+113.9%
19.6%CN¥168.00CN¥80.50n/a19
Feb ’25CN¥55.80
CN¥118.97
+113.2%
19.3%CN¥168.00CN¥80.50n/a18
Jan ’25CN¥72.76
CN¥119.50
+64.2%
18.7%CN¥168.00CN¥86.20n/a18
Dec ’24CN¥83.00
CN¥121.24
+46.1%
18.3%CN¥168.00CN¥86.20n/a17
Nov ’24CN¥84.95
CN¥120.62
+42.0%
19.0%CN¥167.00CN¥86.20CN¥51.1517
Oct ’24CN¥86.18
CN¥115.24
+33.7%
21.5%CN¥171.00CN¥70.80CN¥52.3618
Sep ’24CN¥80.16
CN¥115.24
+43.8%
21.5%CN¥171.00CN¥70.80CN¥39.1818
Aug ’24CN¥74.98
CN¥118.04
+57.4%
20.7%CN¥171.00CN¥70.80CN¥42.3016
Jul ’24CN¥62.31
CN¥119.78
+92.2%
19.4%CN¥171.00CN¥67.60CN¥38.6617
Jun ’24CN¥67.10
CN¥118.87
+77.2%
19.3%CN¥171.00CN¥67.60CN¥42.1118
May ’24CN¥67.53
CN¥118.87
+76.0%
19.3%CN¥171.00CN¥67.60CN¥43.6718
Apr ’24CN¥79.50
CN¥123.13
+54.9%
16.4%CN¥171.00CN¥79.30CN¥47.8418
Mar ’24CN¥83.82
CN¥132.16
+57.7%
19.5%CN¥182.79CN¥97.00CN¥55.0215
Feb ’24CN¥93.88
CN¥136.16
+45.0%
19.7%CN¥182.79CN¥97.00CN¥55.8017
Jan ’24CN¥81.00
CN¥132.86
+64.0%
22.6%CN¥182.79CN¥74.00CN¥72.7616
Dec ’23CN¥80.00
CN¥132.86
+66.1%
22.6%CN¥182.79CN¥74.00CN¥83.0016
Nov ’23CN¥81.00
CN¥136.10
+68.0%
22.0%CN¥182.79CN¥74.00CN¥84.9517

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%